drugset / Trial / NCT03806049
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
ENGOT-OV42 / NSGO-AVATAR: This three-arm randomized trial is to demonstrate efficacy of niraparib-bevacizumab-dostarlimab triplet combination against standard of care treatment and to demonstrate efficacy of niraparib-bevacizumab-dostarlimab triplet combination against niraparib-bevacizumab doublet combination for patients with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
Timeline
- Start
- 2019-12
- Primary completion
- 2022-12
- Completion
- 2024-12
Outcome
Outcome not reported
Stopped (Business): “Lack of financial support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Subject | Dostarlimab | Monoclonal antibody | — | Intravenous |
| Subject | Niraparib | Small molecule | — | Oral |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |